-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck Has Initiated MOBILIZE-1 Phase 3 Trial For Single Dose Of V181, An Investigational Quadrivalent Vaccine, For The Prevention Of Dengue Disease Caused By Any Of The Four Dengue Virus Serotypes. Recruitment For The Trial Has Begun, And The First Participants Are Now Enrolling In Singapore

Benzinga·06/12/2025 10:47:44
Listen to the news
  • MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program
  • Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure